#USA #biotech #Boston #28 Capital #Tiger Gene

28 Capital Launches New Venture to Elevate Scientific Advances

Boston, April 16, 2025 — In an exciting development for the biotech industry, 28 Capital, an innovative venture capital firm specializing in life sciences, has announced the launch of a new platform aimed at translating significant scientific discoveries into groundbreaking therapies for patients. Founded by biotech entrepreneur John Boyce and venture capitalist Audrey Warner, the firm previously operated under the name Tiger Gene, where it established a strong portfolio of transformative biotech companies.

With a commitment to addressing substantial unmet medical needs, 28 Capital intends to leverage its established expertise and connections in the scientific community. The company is dedicated to proactively collaborating with academic founders and leading institutions, ensuring that the most promising scientific innovations are effectively brought to market.

At the helm of this new initiative is John Boyce, who serves as both Co-Founder and Managing Partner. An eminent figure in the biotech sector, Boyce possesses an impressive background with over $1.8 billion in exit value from his ventures. His efforts have been instrumental in securing more than $800 million in funding from various sources, including strategic partners and private investors. His dedication to high-velocity outcomes has not gone unnoticed—he has received accolades such as being named one of the Top 15 Technology Luminaries in Massachusetts by the Boston Business Journal and Mass High Tech in 2013. Notably, he holds prominent positions on the boards of NanoMosaic and BrickBio, among others.

Alongside Boyce is Audrey Warner, the other half of the co-founding duo, who plays the role of Co-Founder and Managing Partner. With a robust background in venture capital and corporate strategy, Warner is recognized for her keen ability to identify promising scientific inventions and work collaboratively with their developers to ensure successful scaling and commercialization. Her leadership includes directorship roles in several biotech firms, including Valora Therapeutics, NanoMosaic, and EnCapsid Therapeutics, as well as serving as a Board Observer for BrickBio.

In Boyce's own words, "At 28 Capital, we believe that the future of medicine is already sitting in academic labs—our job is to unlock it, scale it, and deliver it to patients." This statement epitomizes the firm's mission—transforming innovative ideas into accessible treatments for the public.

The new platform promises to embody a model of venture creation that combines strategic capital with hands-on involvement in the development of biotech firms. 28 Capital envisions closely partnering with a network of world-class scientists, culminating in the formation of companies built from the ground up with the ultimate goal of patient-centricity.

Audrey Warner underscores this philosophy by stating, "It's not just about capital; it’s about conviction, execution, and a deep commitment to patient outcomes." This sentiment reflects the firm’s proactive approach and shared vision for impactful healthcare solutions.

In its forthcoming endeavors, 28 Capital will continue to co-invest alongside leading venture firms, strategic partners, and institutional limited partners (LPs), striving to accelerate the application of breakthrough science within clinical contexts and beyond. As the life sciences sector progresses, 28 Capital positions itself as a key player, equipped to foster the next generation of transformative medical therapies.

For more information about 28 Capital and their latest initiatives, you can visit their website at 28cap.com.

Conclusion
As 28 Capital embarks on this ambitious journey, their vision reflects a promising future for the convergence of science and strategic investment in the biotech realm. The firm’s resolute commitment to nurturing impactful science underscores a significant shift towards innovative healthcare solutions that hold the potential to change lives.